"Not So Different:" Addressing Misinformation on Biosimilars

Last year, biosimilar developer Pfizer submitted a citizen petition to the FDA in which it called on the agency to issue guidance clarifying how drug sponsors can communicate about biosimilars. According to Pfizer, misleading statements were creating create undue confusion about these products. After the petition was filed, The Center for Biosimilars^® invited an expert group of stakeholders to discuss misinformation about biosimilars as well as what steps are necessary to root out and address the misinformation.

This time on the podcast, we’re sharing a portion of that discussion with our listeners.

Want to hear more of the discussion? Click here for video of the full panel.